Jagmeet Singh, HRS 2019 – Findings from the MADIT CHIC Study
We spoke to Dr Jagmeet Singh (Associate Chief, Cardiology Division, Massachusetts General Hospital, Boston, MA, USA) at the recent Heart Rhythm 2019 about the findings of the Multicenter Automatic Defibrillator Implantation Trial – Chemotherapy-induced Cardiomyopathy (MADIT CHIC) and how they might be interpreted in practice. Dr Singh also touches on the current unmet needs in chemotherapy-induced cardiomyopathy.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Jagmeet Singh consults for Abbott, Back Beat, Biotronik, Boston Scientific, EBR, Impulse Dynamics, Medtronic, Microport and Toray, and received research grants from Abbott and Boston Scientific. The study discussed was supported by an investigator-initiated research grant from Boston Scientific.
1. What were the findings of the Multicenter Automatic Defibrillator Implantation Trial ‒ Chemotherapy-induced Cardiomyopathy (MADIT CHIC) study? (0:09)
2. How should these findings be interpreted in practice and how can they help optimise treatment selection in this patient population? (1:49)
3. What are the current unmet needs in chemotherapy-induced cardiomyopathy? (2:35)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Devices
Gregg Stone, ACC 2023: Transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure
Transcatheter edge-to-edge repair (TEER) is a minimally invasive procedure that can effectively treat functional mitral regurgitation in heart failure patients. Compared to traditional surgical approaches, TEER offers benefits such as reduced hospital stay, lower risk of bleeding and infection, and faster recovery time. Additionally, TEER has been found to improve symptoms and quality of life […]
Andrew Krahn: Heart Rhythm 2023 & HRX 2023 – The latest Innovations in arrhythmia care and technology
Dr Andrew Krahn, President, Heart Rhythm Society (HRS), discusses the upcoming Heart Rhythm 2023 meeting (May 19-21, 2023, New Orleans, LA, USA), and the HRX 2023 conference (September 21-23, 2023, in Seattle, WA, USA) hosted by the Heart Rhythm Society (HRS), a non-profit organization dedicated to improving the care of patients with heart rhythm disorders […]
Steven Messe, TCT 2022: Sentinel® cerebral protection system efficacy in reducing all stroke/disabling stroke, the PROTECTED-TAVR trial (a neurologist’s perspective)
The PROTECTED-TAVR trial studied the efficacy of using an embolic protection device (Sentinel® cerebral protection system) during transcatheter aortic valve replacement in reducing the incidence of stroke/disabling stroke. In this touchCARDIO interview, we speak with Dr Steven Messe (University of Pennsylvania, Philadelphia, PA, USA) to give a Neurologist’s perspective on the findings of the PROTECTED-TAVR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!